
Releases
Accord BioPharma Launches Interchangeable Denosumab Biosimilars
Expanding the market for bone health treatments, Accord BioPharma has officially released OSVYRTI and JUBEREQ, two interchangeable biosimilars for Prolia and XGEVA. The launch signals a strategic push by the U.S. specialty division of Intas Pharmaceuticals to lower costs for patients managing osteoporosis and cancer-related bone complications.





















